Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Imitrex Articles

FDA YEAR-END APPROVALS FOR 1993

10 January 1994

EUROPE STOCK COMMENT

10 January 1994

ANALYSTS FORECAST FDA YEAR-END APPROVALS

13 December 1993

GLAXO REAFFIRMS COMMITMENT TO R&D

6 December 1993

STRONG PERFORMANCE FROM GLAXO, AND ZANTAC

13 September 1993

US DRUGSTORE AUDIT DATA FOR JULY

6 September 1993

WILL THERE BE MORE FLEXIBILITY AT GLAXO UNDER SYKES?

28 June 1993

GLAXO'S SINGAPORE PLANT SET FOR 1994

15 February 1993

ANALYST TIPS GLAXO FOR CONTINUED SUCCESS

15 February 1993

FDA APPROVES 26 NEWDRUGS IN 1992

25 January 1993

IMITREX SLOW TO GROW, SAY ANALYSTS

18 January 1993

FDA YEAR-END DRUG APPROVALS ROLL-OUT

4 January 1993

UK FIRMS BOOSTED BY YEAR-END US APPROVALS

4 January 1993

GLAXO'S IMITREX GETS FDA BACKING IN USA

14 December 1992

LONDON STOCK COMMENT

14 December 1992

US PRICE MODERATION "VARIES BY COMPANY"

3 August 1992

US PRICE MODERATION "VARIES BY COMPANY"

3 August 1992

GLAXO PROSPECTS GLOOM: FACT OR FICTION?

3 August 1992

GLAXO INCREASES CNS EMPHASIS IN USA

13 January 1992

Showing 101-119 of 119 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS